IgA Nephropathy

IgA Nephropathy is a type of kidney disease where IgA antibodies build up in the kidneys. This can cause blood in the urine and sometimes lead to kidney failure over time. It's often called Berger's Disease.

Condition

What people with IgA Nephropathy report

Every report comes from a Lived member, sent anonymously.

Have you tried Cozaar (Losartan) for IgA Nephropathy?

NameHow it went

About IgA Nephropathy

What It Is

IgA nephropathy, also called Berger's disease, is a long-term kidney disease in which the immune system damages the kidneys' filters. Immunoglobulin A (IgA) is an antibody that normally helps protect the lining of the nose, throat and gut. In IgA nephropathy, a faulty form of IgA clumps together with other antibodies, and these clumps settle in the glomeruli, the tiny looping blood vessels that filter waste from the blood. The inflammation that follows lets blood and protein leak into the urine and, over years, can scar the kidneys and reduce how well they work. Many people have no symptoms for years. The disease is most often found when a routine urine test finds blood too small to see, or protein, in the urine. Others notice episodes of pink or cola-colored urine, typically at the same time as a cold, sore throat or stomach infection. Foamy urine, swelling in the legs or around the eyes, and high blood pressure can appear as damage increases. IgA nephropathy is one of the most common immune-related kidney diseases worldwide, and its course ranges from mild and stable to steadily progressive.

Causes & Risk Factors

The exact cause isn't known. Research points to a mix of inherited tendencies and environmental factors that lead the body to make IgA that is prone to forming these clumps. IgA nephropathy is not contagious, and researchers have not found that diet causes or prevents it. It is more common in males, in people between about 10 and 40 years old, and in people of East Asian or white European ancestry. A family history of IgA nephropathy, or of IgA vasculitis (a related condition that affects blood vessels throughout the body as well as the kidneys), raises the likelihood. It can also develop alongside other conditions, including celiac disease, chronic liver disease such as cirrhosis, and HIV (human immunodeficiency virus) infection. Infections are not known to cause the disease, but in someone who already has it, a cold, sore throat or other infection can bring on an episode of visible blood in the urine.

How It's Diagnosed

Suspicion usually begins with urine and blood tests. A urinalysis looks for red blood cells and protein in the urine. Protein loss is then measured more precisely, often from a single urine sample that compares protein with creatinine (the urine protein-to-creatinine ratio), and is expressed as grams of protein lost per day. Persistent loss of 0.5 grams a day or more is the level at which specialists recommend confirming the cause. Blood and protein in the urine have many possible causes, so these findings alone do not establish IgA nephropathy. A blood test for creatinine, a waste product from muscle, is used to estimate the glomerular filtration rate (eGFR), a measure of how well the kidneys filter. An eGFR of 60 or more is not by itself in the kidney disease range, although blood or protein in the urine can still signal kidney disease. A value below 60 may mean kidney disease, and 15 or less is kidney failure. Only a kidney biopsy confirms IgA nephropathy. After a numbing injection, and usually guided by ultrasound, a doctor uses a needle to take a few tiny pieces of kidney tissue, which a pathologist examines for IgA deposits. The biopsy also shows how much active inflammation and scarring is present, which helps predict how the disease is likely to behave and guides the choice of treatment.

Treatment Options

There is currently no cure, but treatment can prevent or delay kidney damage. Care is usually led by a nephrologist (kidney specialist). The main sign that treatment is working is less protein in the urine: current international guidelines aim for under 0.5 grams a day, ideally under 0.3 grams, with eGFR holding steady. Treatment works on two fronts. The first protects the kidneys from ongoing strain. This includes controlling blood pressure, most often with an ACE (angiotensin-converting enzyme) inhibitor or an angiotensin receptor blocker (ARB), medicines that lower blood pressure and also reduce protein leakage; limiting salt; not smoking; and a statin when cholesterol needs lowering. SGLT2 (sodium-glucose cotransporter-2) inhibitors such as dapagliflozin (Farxiga), first developed for diabetes, are approved to slow chronic kidney disease and are often added. Sparsentan (Filspari) is a daily tablet that blocks two hormones, endothelin and angiotensin, that drive protein leakage; it is approved to slow kidney function decline in adults at risk of progression and it replaces an ACE inhibitor or ARB rather than being taken alongside one. Atrasentan (Vanrafia) is taken alongside an ACE inhibitor or ARB and blocks endothelin alone, one of the two hormones sparsentan blocks, to reduce protein leakage. It is approved because it lowers protein loss; whether it slows kidney function decline over the long term is still being confirmed. The second front targets the immune process itself, usually for people who still lose significant protein despite those measures. Targeted-release budesonide (Tarpeyo) is a corticosteroid capsule taken once a day for nine months. It is designed to act mainly in the lower small intestine, where immune cells make the faulty IgA, and is approved to reduce loss of kidney function. Steroid tablets that act throughout the body, such as prednisone, are sometimes used at reduced doses, but serious infections are a real risk, so the decision is weighed carefully. Iptacopan (Fabhalta) is a twice-daily capsule that blocks part of the complement system, a set of immune proteins that adds to inflammation in the kidney. It is approved to slow kidney function decline, and because it raises the risk of serious bacterial infections, specific vaccinations must be up to date before starting. A newer medicine, sibeprenlimab (Voyxact), an injection given every four weeks that blocks a signal the immune system uses to make IgA, is approved because it lowers protein loss; whether it slows kidney function decline over the long term is still being confirmed. Sparsentan and atrasentan can cause serious birth defects, so pregnancy must be ruled out before starting and effective contraception used during treatment. Sparsentan also requires regular liver blood tests. The approvals for these IgA nephropathy medicines are for adults; children are treated on the basis of more limited evidence.

What to Expect

IgA nephropathy is a long-term condition with a wide range of outcomes. Some people keep stable kidney function for many years, while others lose function gradually. The risk of losing kidney function is much higher when urine protein stays at about 0.5 grams a day or more, which is why treatment aims to bring it lower. Older studies that included many people with mild disease found that about 1 in 5 people developed kidney failure within 10 years of diagnosis; in higher-risk groups, recent reviews put the figure as high as half within 10 years. The biopsy findings, together with how much protein is in the urine and how well the kidneys are filtering, help a specialist estimate which course is more likely, and those estimates are revisited as results change. Many people feel well day to day, so the disease is managed mainly through regular blood pressure checks and repeated urine protein and eGFR tests, more often when a treatment is starting or changing. Many people check their blood pressure at home and keep salt intake low. Episodes of visible blood in the urine can recur with infections. Anyone hoping to become pregnant should plan ahead with the kidney team, since some treatments must be stopped beforehand. If kidney failure develops, dialysis or a transplant is needed. IgA nephropathy can come back in a transplanted kidney and is an important cause of early transplant loss, so monitoring continues after a transplant.

When to Seek Help

Arrange a medical evaluation if you notice pink, red or cola-colored urine, persistently foamy urine, or new swelling in your legs, ankles or around your eyes, or if a routine test shows blood or protein in your urine. If you already have IgA nephropathy, contact your care team when home blood pressure readings stay above your agreed target, and promptly if you become pregnant or think you might be while taking an ACE inhibitor, ARB, sparsentan or atrasentan. Contact your care team the same day if you are passing much less urine than usual or if swelling or weight builds up quickly over a few days, since kidney function can occasionally fall suddenly.

Questions to Ask Your Doctor

  1. 1.What did my biopsy show about active inflammation compared with scarring, and what does that mean for my outlook?
  2. 2.What is my current urine protein level, and what target are we aiming for?
  3. 3.Am I at risk of the disease progressing, and would a treatment that targets the immune process help me, in addition to blood pressure control?
  4. 4.How would my treatment affect plans for pregnancy, vaccinations or other medicines I take?
  5. 5.How often should my blood and urine be tested, and which results or symptoms should prompt me to call?

Last reviewed • Oct 2026

Educational content, not medical advice.